Oct 15 (Reuters) - Transition Therapeutics Inc TTH.TO :
* Press release - Transition Therapeutics announces results of data analysis
from elnd005 phase 2/3 clinical study in agitation and aggression in
alzheimer's disease patients
* Announces results of data analysis from elnd005 phase 2/3 clinical study in
agitation and aggression in alzheimer's disease patients
* Says primary efficacy endpoint not achieved in overall study
* Says elnd005 demonstrated acceptable safety and tolerability profile
* Says elnd005 was shown to have an acceptable safety and tolerability profile
in the study
* Says company intends to meet with regulators to seek guidance on elnd005
phase 3 program
* Source text for Eikon urn:newsml:reuters.com:*:nPnchlTY
* Further company coverage TTH.TO